Ureteral Stents Market Insights, Trends & Growth Outlook 2022-2029

SKU: DMMD1957 | Last Updated On: Jun 23 2022 | Available Formats

> Global Ureteral Stents Market Expected to reach a high CAGR of ~5.8% By 2029 | DataM Intelligence

Global Ureteral Stents Market is segmented By Product type (Multiloop, Open-end stents, Closed-end stents, Double pigtail stents), By Material (Metal stents, Silicone stents, Hybrid stents, Polyurethane stents, Others), By Application (Kidney stones, Kidney transplantation, Tumors, Urinary incontinence, Others), By End-User (Hospitals, Clinics, Ambulatory surgical centers, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029


Market Overview

The Global "Ureteral Stents Market" is expected to grow at a CAGR of 5.8% during the forecasting period (2022-2029).

Ureteral stents are thin, flexible tubes, used to restore urine flow through blocked ureters due to various disorders. Innovative interface platforms available in the market for stent case management and patient safety are useful for both patients and physicians. Epidemiological data revealed that the prevalence of kidney stone disease is increasing, which further increases the demand for ureteral stents in the future.

Market Dynamics

The global ureteral stents market is driven by the rising incidence of urological diseases, rising geriatric population with kidney disorders, an increasing number of kidney transplants.

The increasing number of kidney transplants is expected to drive the market. For instance, the National Kidney Foundation reported that in 2016, there are currently 121,678 people waiting for lifesaving organ transplants in the US. Of these, 100,791 awaits kidney transplants. The median wait time for an individual's first kidney transplant is around 3.6 years and vary depending on compatibility, health, availability of organs. According to the report published by NHS Blood and Transplant, which works in collaboration with NHS England, on March 31, 2017, there were 4,915 adult patients on the UK active kidney transplant list. Thus, the growing number of renal transplants and raising concerns related to urological dysfunctioning has surged the demand for ureteral stents for post-operative convenience.

The growing geriatric population is expected to drive the global ureteral stents market. For instance, As per World Health Organization, the number of people aged 65  is expected to rise from an estimated 524 million in 2010 to nearly 1.5 billion in 2050, with most of the increase in developing countries. This increase in the number of geriatric will be reflected by the rise in medical problems such as kidney stones. It requires coordinated care by multiple specialties, with geriatricians and nephrologists playing a vital role in the treatment of these patients. According to an article published in the International Brazilian Journal of Urology, in the UK those aged 75 are expected to double from 5.2 million in the year 2014 to 9.9 million by 2039. The number of ureteroscopic stone treatments has raised by 252% between 1996 and 2016. Thus, there is an increasing burden of urinary tract stone disease and a rising trend towards surgical management, of which ureteroscopy (URS) is the fastest-growing intervention.

Moreover, the growing prevalence of urological and kidney-related disorders is expected to increase the demand for ureteral stents over the period of forecast. For instance, the National Center for Biotechnology Information reported that in October 2018, an estimated 1 to 19% of the population in India is suffering from urolithiasis.

However, the high risk of complications after the removal of stents is likely to restrain the market. Some complications related to dislocation, blockage, and infection may arise because of the usage of a urinary stent. The patient may also feel an increased urgency or frequency of urination, kidney pain, and blood in the urine. These factors surge the medical research and development departments to still come out with a better alternative to ureteral stents and can affect the market growth in the forecast period.

Market Segmentation

By product type, the global ureteral stents market is segmented into open-end stents, closed-end stents, double pigtail stents, and multi-loop stents.

The multiloop stents segment is expected to grow at the highest rate due to the rise in the prevalence of urological disorders, growing geriatric population, technological advancements in the multiloop stents segment associated with reduced complications. Also, the high adoption of these stents and the adoption of various marketing strategies by critical vendors foster its growth. The Multiloop Ureteral Stent is intended to temporarily facilitate drainage of urine from kidney to bladder by a trained physician. On the multiloop ureteral stents front, one of the market leaders is MEDpro Medical with their successful Double J Stent one end multiple loop and  Double J Stent both end multiple loop products. Also, Biliary double J stent, both end multiple loops of Surgimedik is one of a kind.

The kidney transplantation segment is expected to boost the market over the period of forecast. For instance, Global Observatory on Donation and Transplantation reported that in 2016, around 89,823 kidney transplant surgeries were done worldwide in 2016, which was an increase of 6.5% from 2015.

Geographical Analysis

North America is dominating the global ureteral stents market in 2018 and estimated to hold significant market size over the forecast period (2020-2027) owing to the rising incidences of urological diseases like chronic kidney diseases, kidney stones, etc., rising geriatric population base, increasing sedentary lifestyles, growing kidney transplantations.

The major players are adopting various strategies, including product launch, company expansion, mergers, and others, which are also fuelling the growth of the market. For instance, University Hospitals Cleveland Medical Center is developing the RELIEF™ Ureteral Stent, which is in clinical trials, to assess Retrograde Urinary Reflux and Distal Coil Bladder Position. It is a single-use, disposable ureteral stent device which provides the traditional function of allowing the passage of urine from the kidney to the bladder with new design enhancements, also with the benefits of minimizing urinary reflux and decreasing irritative bladder symptoms to improve the patient care. According to the reports, the estimated study completion date is April 2020.

On March 2, 2016, Boston Scientific had launched a new application, called the Ureteral Stent Tracker, that aids urologists and their staff keep tabs on ureteral stents implanted in patients with kidney stones. The application was developed in partnership with health app developer Visible Health.

On the ureteral stents front, the clear market leader is Boston Scientific with their successful Percuflex™, Contour™, and Polaris™ families of products.

On 7 January 2019, Boston Scientific has launched LithoVue Empower retrieval deployment device. It is used with the LithoVue single-use digital flexible ureteroscope during ureteroscopic kidney stone retrieval procedures.

Competitive Landscape

The major players operating in the global ureteral stents market are Boston Scientific Corporation, B. Braun Holding GmbH & Co. KG, Cook Group Incorporated,  Coloplast Ltd., C. R. Bard, Inc., Medline Industries, Inc., Allium Medical Solutions Ltd, Pnn Medical A/S, Teleflex Incorporated, and Olympus Corporation.

The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, which are contributing to the growth of the ureteral stents market globally. For instance, In January 2019, QUrological Corporation has developed an aqueous hydrogel biomaterial, pAguamedicina, also patented the processing method to produce very high aqueous content to produce the100% hydrogel catheters and stents.

In June 2019, Merit Medical Systems, Inc. has acquired Brightwater Medical, Inc., to align the former's resolve drainage catheter portfolio with Brightwater's ConvertX biliary stent system.

In June 2018, HydrUStent developed Hydrustent Biodegradable Ureteral Stent, which prevents the need for a second surgery for stent removal, also prevents bacterial colonization and biofilm formation, which leads to infection.

In 2018, Q Urological Corporation announced the first human placement of its AguaMedicina PERSISTENT Structural Hydrogel Ureteral Stent.

In 2017, Q Urological Corporation received the FDA approval for its new AguaMedicina PERSISTENT Structural Hydrogel Ureteral Stent.

On December 1, 2016, Brightwater Medical announced that the FDA cleared the company's innovative ConvertX Nephroureteral stent system for the treatment of ureteral obstructions.

Trending Topics

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!